AU2021253674A1 - Ofatumumab for treating MS while maintaining serum IgG - Google Patents

Ofatumumab for treating MS while maintaining serum IgG Download PDF

Info

Publication number
AU2021253674A1
AU2021253674A1 AU2021253674A AU2021253674A AU2021253674A1 AU 2021253674 A1 AU2021253674 A1 AU 2021253674A1 AU 2021253674 A AU2021253674 A AU 2021253674A AU 2021253674 A AU2021253674 A AU 2021253674A AU 2021253674 A1 AU2021253674 A1 AU 2021253674A1
Authority
AU
Australia
Prior art keywords
ofatumumab
cell
treatment
patients
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021253674A
Other languages
English (en)
Inventor
Martin MERSCHHEMKE
Ratnakar PINGILI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2021253674A1 publication Critical patent/AU2021253674A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021253674A 2020-04-09 2021-04-09 Ofatumumab for treating MS while maintaining serum IgG Pending AU2021253674A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP20169007.0 2020-04-09
EP20169007 2020-04-09
EP20176057 2020-05-22
EP20176057.6 2020-05-22
US202063076628P 2020-09-10 2020-09-10
US63/076,628 2020-09-10
US202163166054P 2021-03-25 2021-03-25
US63/166,054 2021-03-25
PCT/EP2021/059285 WO2021204994A1 (en) 2020-04-09 2021-04-09 Ofatumumab for treating ms while maintaining serum igg

Publications (1)

Publication Number Publication Date
AU2021253674A1 true AU2021253674A1 (en) 2022-11-03

Family

ID=75362645

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021253674A Pending AU2021253674A1 (en) 2020-04-09 2021-04-09 Ofatumumab for treating MS while maintaining serum IgG

Country Status (12)

Country Link
US (1) US20230151106A1 (https=)
EP (3) EP4707302A2 (https=)
JP (2) JP7794757B2 (https=)
KR (1) KR20220166827A (https=)
CN (1) CN115427068A (https=)
AU (1) AU2021253674A1 (https=)
BR (1) BR112022019038A2 (https=)
CA (1) CA3176574A1 (https=)
DE (1) DE202021004005U1 (https=)
IL (1) IL296701A (https=)
MX (1) MX2022012600A (https=)
WO (1) WO2021204994A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3733712T (lt) 2016-08-15 2023-09-11 Novartis Ag Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą
US20220389109A1 (en) * 2019-09-11 2022-12-08 Novartis Ag Management of conditions other than multiple sclerosis in ofatumumab-treated patients
WO2022219057A1 (en) * 2021-04-14 2022-10-20 Novartis Ag Ofatumumab for treating multiple sclerosis in asian patients

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0315295C1 (pt) 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
WO2012018704A1 (en) * 2010-08-02 2012-02-09 Sanofi-Aventis U.S. Llc Use of teriflunomide for treating multiple sclerosis
EP2748198A2 (en) * 2011-09-27 2014-07-02 The United States of America, as represented by The Secretary, Department of Health and Human Services Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis
LT3733712T (lt) * 2016-08-15 2023-09-11 Novartis Ag Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą
MX2022003010A (es) * 2019-09-11 2022-06-02 Novartis Ag Tratamiento de la emr mediante cambio de terapia.
US20220389109A1 (en) * 2019-09-11 2022-12-08 Novartis Ag Management of conditions other than multiple sclerosis in ofatumumab-treated patients
WO2022219057A1 (en) * 2021-04-14 2022-10-20 Novartis Ag Ofatumumab for treating multiple sclerosis in asian patients
US20240343821A1 (en) * 2021-08-16 2024-10-17 Novartis Ag Ofatumumab for treating pediatric ms

Also Published As

Publication number Publication date
JP2023521754A (ja) 2023-05-25
EP4682171A2 (en) 2026-01-21
DE202021004005U1 (de) 2022-05-06
BR112022019038A2 (pt) 2022-11-01
EP4682171A3 (en) 2026-05-06
CA3176574A1 (en) 2021-10-14
US20230151106A1 (en) 2023-05-18
WO2021204994A1 (en) 2021-10-14
EP4132564A1 (en) 2023-02-15
JP7794757B2 (ja) 2026-01-06
MX2022012600A (es) 2023-02-15
EP4707302A2 (en) 2026-03-11
KR20220166827A (ko) 2022-12-19
IL296701A (en) 2022-11-01
JP2026009900A (ja) 2026-01-21
CN115427068A (zh) 2022-12-02

Similar Documents

Publication Publication Date Title
JP2026009900A (ja) 血清ＩｇＧを維持しながらＭＳを治療するためのオファツムマブ
EP3864053B1 (en) Treatment of rms by switching therapy
US20240228647A1 (en) Ofatumumab for treating multiple sclerosis in asian patients
Gensicke et al. Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis
EP4387999A1 (en) Ofatumumab for treating pediatric ms
TW202300523A (zh) 用於治療MS同時維持血清IgG之奧法木單抗(OFATUMUMAB)
BR122024017958A2 (pt) Usos de ofatumumab para tratamento de esclerose múltipla (em) enquanto mantém a igg sérica
JP2024517796A (ja) 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療
KR20250135226A (ko) 자가면역 질환의 치료를 위한 항-cd38 항체
HK40051003B (en) Treatment of rms by switching therapy
HK40051003A (en) Treatment of rms by switching therapy
CN117015397A (zh) 用于治疗狼疮的方法和组合物
CN121843712A (zh) 用于治疗多发性硬化症的组合物和方法
CN117813328A (zh) 用于治疗儿童ms的奥法妥木单抗